Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2011 Results
Date:5/5/2011

ROCKVILLE, Md., May 5, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2011.

"We are very excited about the significant progress we have made to date in 2011," said Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer. "Our first product, Fanapt®, which is marketed in the U.S. for the treatment of schizophrenia has now entered a Phase I study to evaluate the safety and pharmacokinetic profiles of two different long-acting formulations in patients with schizophrenia.  In addition, we have expanded the tasimelteon clinical program with a Phase IIb/III Study in Major Depression that will begin in the second half of 2011."

Key Highlights:

  • Vanda recorded first quarter 2011 revenue of $7.5 million including royalties of $0.9 million. Fanapt® prescriptions, as reported by IMS, reached 25,000 in the first quarter of 2011.
  • Fanapt® long-acting injectable (depot) formulation advanced into clinical studies.
  • European filing for oral Fanapt® is targeted for the second half of 2011.
  • Tasimelteon program expanded to include a Phase IIb/III study in patients with Major Depressive Disorder.   Study expected to begin in the second half of 2011.
  • The European Commission (EC) granted orphan drug designation for tasimelteon for Non-24-Hour Sleep/Wake Disorder (N24HSWD.)  
  • Top-line efficacy results for tasimelteon for N24HSWD are expected in mid 2012; NDA submission planned for the first half of 2013.

  • FIRST QUARTER 2011 REPORTED RESULTSTotal revenues for the first quarter of 2011 were $7.5 million, com
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
    2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
    3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
    4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
    5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
    6. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
    7. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
    8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
    9. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
    10. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
    11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix ... it has completed a collaborative research program ... analytics.  Using Fast Collective Evolution Technology (FACET), ... including all measurements obtained from each of ... Phase 2 clinical trials ASSERT, SUSTAIN and ...
    (Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
    (Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
    (Date:3/4/2015)... 2015 Follow us on LinkedIn ... the fastest growing technologies in the life sciences industry. ... is driving growth in nucleic acid detection technologies like ... gene expressions will continue to benefit the qPCR and ... ranging from pharma, biotech, food & beverage to animal ...
    Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
    ... LLC (L3I) has,successfully completed the Quality Management System (QMS) ... ISO 9001 and AS 9100,Certification under the rules of ... compliance and zero non-compliance issues. , ... Operations, Scott McAfee led,the creation, organization and refinement of ...
    ... Pharmaceuticals Inc.,is pleased to announce the appointment of Barry ... draw upon his 24 years of pharmaceutical sales and,marketing ... products for the company. , ... "We are extremely pleased to welcome Mr. ...
    ... 13 Johnston Blakely & Company, LLC, a,Boston-based ... that Michael,D. Webb has joined the firm as ... will,participate with the firm on internal and client-related ... equity placements, with a,particular focus on biopharmaceutical transactions. ...
    Cached Biology Technology:Level 3 Inspection Achieves 100% Compliance in ISO 9001 & AS 9100 Certification 2
    (Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
    (Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ... its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . ... of production capacity to meet customer demand. ... - http://photos.prnewswire.com/prnh/20150113/168790 Invented ...
    (Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
    Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
    ... headed by Dr. Sara Melville at the University of ... African sleeping sickness has evolved an unusual chromosomal structure ... parasite, the chromosomes are highly enriched in subtelomeric sequences ... to the gene-rich cores. These subtelomeres, in some ...
    ... the Pacific Northwest Research Institute (PNRI) and the National ... pattern of DNA damage in connective tissues in the ... stages of breast cancer and possibly serve as an ... In the United States, breast cancer is the second ...
    ... years, researchers have struggled to understand how IVIG worked. ... bean apparent contradiction. , Intravenous immunoglobulin (IVIG) is ... plasma that contains the pooled antibodies from thousands of ... assorted conditions; nonetheless, practitioners have used it off-label with ...
    Cached Biology News:DNA to the defense 2Links between DNA damage and breast cancer studied 2A single sugar found responsible for an antibody's ability to treat inflammation 2A single sugar found responsible for an antibody's ability to treat inflammation 3
    DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Yersinia pestis...
    Insect Cell Lysis Buffer 50 ml...
    Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
    Biology Products: